Calidi Biotherapeutics' (CLDI) shares fell by more than 30% in premarket trading on Friday after the company priced a public offering of 5 million shares at $0.85 each.
Gross proceeds from the offering are expected to be about $4.25 million and the company said it will use the net proceeds for working capital and general corporate purposes.
The offering is expected to close Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。